{"disease":{"id":"familial-alcoholism-vulnerability","name":"familial alcoholism vulnerability"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05203965","title":"Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT03341715","title":"Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Yale University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}